The Ark
A blog about our science, the rare disease community and PerlQuests
Why Y Combinator?
11-year old startup accelerator Y Combinator – “YC” for those in the know – has...
From primary screen to mouse validation, Part Two
Five months ago we introduced PERL101, one of our lead compounds for Niemann-Pick...
DMSO and Drug Discovery
Dimethly Sulfoxide, commonly known as DMSO, is a small molecule composed of two...
Last quarter in tweets
"Last month in tweets" took a hiatus in the first quarter of 2016, but now it's back!...
A vision for Perlstein Lab
Today's post will focus on the vision for PLab. Let's start with a basic statistical...
2015 burn rate
As a Public Benefit Corporation, transparency is a common thread tying our missions...
2015 in review
Feels like the last 12 months went by in a flash! When I wrote this post a year ago,...
CRISPR genome editing to make an NGLY1 fly
N-glycanase 1 deficiency, or “NGLY1,” is a rare genetic disorder arising from...
From primary screen to mouse validation
PERL101 is one of our lead compounds for Niemann-Pick C. We discovered it in a whole...
October in tweets
Over the summer we completed the hit-to-lead phase of our NPC discovery program, and...
The value of a Virtual Lab Manager
Back in 2014 when PLab was first funded, one of the first hires wasn't an employee,...
PLab platform white paper
Summary Perlstein Lab PBC (PLab) is Delaware public benefit corporation accelerating...
